CureVac's COVID-19 vaccine misses efficacy goal in pivotal trial

Credit: REUTERS/KAI PFAFFENBACH

German biotech CureVac NV said on Wednesday its COVID-19 vaccine was only 47% effective in a late-stage trial, missing the study's main goal and throwing in doubt the potential delivery of hundreds of millions of doses to the European Union.

Adds trial details

June 16 (Reuters) - German biotech CureVac NV 5CV.DE said on Wednesday its COVID-19 vaccine was only 47% effective in a late-stage trial, missing the study's main goal and throwing in doubt the potential delivery of hundreds of millions of doses to the European Union.

The disappointing efficacy of the shot known as CVnCoV emerged from an interim analysis based on 134 COVID-19 cases in the study with about 40,000 volunteers in Europe and Latin America.

As CureVac's only major supply deals, the European Union in November secured up to 405 million doses of the vaccine, of which 180 million are optional. That was followed by a memorandum of understanding with Germany for another 20 million doses.

The company said at least 13 virus variants accounted for the infections among the study population, adding that the original version of the coronavirus that emerged in Chinese city of Wuhan in late 2019 had been "almost completely absent" in the trial so far.

CureVac's U.S. traded shares fell 48% to $49.00 in after-hours trading following the publication of the data.

(Reporting by Ludwig Burger Editing by Chris Reese and Bill Berkrot)

((ludwig.burger@thomsonreuters.com; +49 30 220133634; Reuters Messaging: ludwig.burger.thomsonreuters.com@reuters.net))

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story

CVAC

Reuters

Reuters, the news and media division of Thomson Reuters, is the world’s largest international multimedia news provider reaching more than one billion people every day. Reuters provides trusted business, financial, national, and international news to professionals via Thomson Reuters desktops, the world's media organizations, and directly to consumers at Reuters.com and via Reuters TV.

Learn More